2Barden J, Edwards JE, McQuay HJ, Moore RA. Single Dose Oral Celecoxib for Postopreative Pain (Cochrane Reviw). In: The Cochrane Library, Issue 1, 2005. Chichester, UK: John Wiley & Sons, Ltd.
3Farley Dixie. Benefit vs. Risk: How FDA Approves New Drugs [EB/OL]. FDA Consumer Special Report. 1995 Jan. Available from: URL: http://www.fda.gov/fdac/special/new drug/benefits.html.
4Langley PC. Pharmacoeconomics in Drug Development and Marketing: An Overview. ISPOR Distance Learning Program. Monograph. 2004.
5Langley PC. Pharmacoeconomics in Market Entry and Market Support. ISPOR Distance Learning Program. Monograph. 2004.
6Barden J, Edwards J, Moore RA, McQuay HJ. Single Dose Oral Rofecoxib for Postoperative Pain (Cochrane Reviw). In: The Cochrane Library, Issue 1, 2005. Chichester, UK: John Wiley & Sons, Ltd.
7Jackson CM, Lipworth B. Benefit-risk assessment of long-acting beta2-agonists in asthma[J]. Drug Saf, 2004; 27(4): 243-270.
8Lila Assiff, Michael R Pollock, Patricia Manzi,et al. Health Economics in the Canadian pharmaceutical industry [J].Pharmacoeconomics, 1999, 16(6):669-678.
9Naoki Ikegami, Michael Drummond, Shunichi Fukuhara ,et al. Why has the use of Health Economic Evaluation in Japan lagged behind that in other developed countries[J]?Pharmacoeconomics, 2002, 20(Suppl2):2.
